Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:00:30 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:VXRT - VAXART INC - http://www.vaxart.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VXRT - Q0.10.7128·0.71543.30.7143-0.0347-4.61,862.21,1522,5290.749  0.7494  0.691.59  0.5315:42:39Apr 3015 min RT 2¢

Recent Trades - Last 10 of 2529
Time ETExPriceChangeVolume
15:42:39Q0.713-0.0362,138
15:42:39Q0.713-0.03662
15:42:39Q0.713-0.036100
15:42:39Q0.713-0.036100
15:42:39Q0.7129-0.0361100
15:42:39Q0.713-0.036100
15:42:39Q0.713-0.036100
15:42:39Q0.713-0.036100
15:42:39Q0.7143-0.0347100
15:42:39Q0.7143-0.0347200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-30 08:01U:VXRTNews ReleaseVaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
2024-03-27 08:00U:VXRTNews ReleaseVaxart to Present at World Vaccine Congress Washington 2024 on April 3
2024-03-20 08:00U:VXRTNews ReleaseVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-14 16:01U:VXRTNews ReleaseVaxart Provides Business Update and Reports Full Year 2023 Financial Results
2024-03-07 08:00U:VXRTNews ReleaseVaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
2024-03-06 08:00U:VXRTNews ReleaseVaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
2024-02-05 08:00U:VXRTNews ReleaseVaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
2024-01-19 08:30U:VXRTNews ReleaseVaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
2024-01-16 09:25U:VXRTNews ReleaseVaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
2024-01-16 09:23U:VXRTNews ReleaseVaxart, Inc. Announces Management Change
2023-12-21 08:00U:VXRTNews ReleaseVaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
2023-11-02 16:01U:VXRTNews ReleaseVaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-11-02 08:00U:VXRTNews ReleaseVaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
2023-10-26 08:00U:VXRTNews ReleaseVaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2
2023-10-11 08:00U:VXRTNews ReleaseVaxart to Present at World Vaccine Congress Europe 2023 ‚  on October 18-19
2023-09-21 08:00U:VXRTNews ReleaseVaxart ‚  to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
2023-09-06 16:05U:VXRTNews ReleaseVaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
2023-08-03 16:01U:VXRTNews ReleaseVaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-07-27 08:00U:VXRTNews ReleaseVaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
2023-07-06 08:00U:VXRTNews ReleaseVaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate